Antimicrobial Resistance Rates of Acinetobacter spp. Isolated from Adult Patients in a State Hospital Between 2017-2021

Öz

Objective: Acinetobacter species lead to extremely serious infections, particularly in hospitalized patients, and in patients with impaired host defense. The high rates of resistance against several antibiotics detected in recent years have created serious issues in treatments of different diseases. We aimed to examine antibiotic resistance profiles of Acinetobacter species isolated from patients who are treated as outpatients in polyclinics or hospitalized in services or intensive care units (ICU), against various antimicrobial therapies. Materials and Methods: Antibiotic resistance of Acinetobacter strains isolated from 533 clinical samples collected between 2017-2021 years in Bandırma State Hospital Clinical Microbiology Laboratory were evaluated retrospectively. The identification of isolates and antibiotic susceptibility tests were performed by BD Phoenix (Becton Dickinson, USA) automated system. Results: Most of Acinetobacter strains were isolated from respiratory secretions (32.5%) and from urine (24.4%). Of species, 63.8% were Acinetobacter baumannii, 34.9% Acinetobacter baumannii complex, 1.1% other Acinetobacter spp., 0.2% Acinetobacter lwoffii. Resistance rates to antibiotics were found as following: ciprofloxacin 91.1%, meropenem 91.3%, imipenem 89.2%, gentamicin 82.5%, trimethoprim-sulfamethaxasol 78.6%, amikacin 66.3% (highest in 2020), aztreonam 99.0% (significantly decreased in 2020), ceftriaxone 100%, ampicillin 100%, amoxicillin-clavulanate 100%, ertapenemicin 100%, cefuroxime 100%, netilmicin 62.5%, nitrofurantion 100%, colistin 4.7% and levofloxacin 87.1%. The samples collected from patients hospitalized in service and ICU were found more resistant against Ciprofloxacin, Levofloxacin, Meropenem, Imipenem, Trimethoprim/Sulfamethoxazole, Gentamicin and Amikacin (P<0.0001). Conclusion: Colistin resistance against Acinetobacter infections was observed to be low, hence colistin could be utilized in treatments. Infection control measures have to be taken in services and ICU, and rational antibiotic use policies should be applied so as to prevent the spread of infection.

Anahtar Kelimeler

• acinetobacter
• acinetobacter baumanii
• nosocomial enfection

2017-2021 Yılları Arasında Bir Devlet Hastanesinde Erişkin Hastalardan İzole Edilen Acinetobacter spp. Antimikrobiyal Direnç Oranları

Öz

Amaç: Acinetobacter türleri, özellikle hastanede yatan hastalarda ve konak savunması bozulmuş hastalarda son derece ciddi enfeksiyonlara yol açmaktadır. Son yıllarda tespit edilen birçok antibiyotiğe karşı yüksek direnç oranları, farklı hastalıkların tedavisinde ciddi sorunlar yaratmıştır. Polikliniklerde ayaktan tedavi edilen veya servislerde veya yoğun bakım ünitelerinde (YBÜ) yatan hastalardan izole edilen Acinetobacter türlerinin çeşitli antimikrobiyal tedavilere karşı antibiyotik direnç profillerini incelemeyi amaçladık. Gereç ve Yöntem: Bandırma Devlet Hastanesi Klinik Mikrobiyoloji Laboratuvarında 2017-2021 yılları arasında toplanan 533 klinik örnekten izole edilen Acinetobacter suşlarının antibiyotik direnci retrospektif olarak değerlendirildi. İzolatların tanımlanması ve antibiyotik duyarlılık testleri BD Phoenix (Becton Dickinson, ABD) otomatik sistemi ile yapıldı. Sonuçlar:Acinetobacter suşlarının çoğu solunum salgılarından (%32.5) ve idrardan (%24.4) izole edilmiştir. Türlerin %63.8'i Acinetobacter baumannii, %34.9'u Acinetobacter baumannii kompleksi, %1.1'i diğer Acinetobacter spp., %0.2'si Acinetobacter lwoffii'dir. Antibiyotiklere direnç oranları şu şekilde bulundu: Siprofloksasin %91,1, meropenem %91,3, imipenem %89,2, gentamisin %82,5, trimetoprim-sülfametaksasol %78,6, amikasin %66,3 (2020'de en yüksek), aztreonam %99,0 (2020'de önemli ölçüde azaldı), seftriakson %100, ampisilin %100, amoksisilin-klavulanat %100, ertapenemisin %100, sefuroksim %100, netilmisin %62.5, nitrofurantion %100, kolistin %4.7 ve levofloksasin %87.1. Serviste ve yoğun bakım ünitesinde yatan hastalardan alınan örneklerde Siprofloksasin, Levofloksasin, Meropenem, İmipenem'e karşı daha dirençli bulundu. Sonuç: Acinetobacter enfeksiyonlarına karşı kolistin direncinin düşük olduğu gözlenmiş, bu nedenle tedavilerde kolistinden yararlanılabilir. Servislerde ve yoğun bakım ünitelerinde enfeksiyon kontrol önlemleri alınmalı ve enfeksiyonun yayılmasını önlemek için akılcı antibiyotik kullanım politikaları uygulanmalıdır.

Anahtar Kelimeler

• acinetobacter
• acinetobacter baumanii
• hastane enfeksiyonu

Kaynakça

1. 1. Rungruanghiranya S, Somboonwit C, Kanchanapoom T (2005). Acinetobacter infection in the intensive care unit. J Infect Dis Antimicrob Agents, 22: 77-92.9.
2. 2. Peleg AY, Seifert H, Paterson DL (2008). Acinetobacter baumannii: emergence of asuccessful pathogen. Clin Microbiol Rev, 21(3): 538-582.
3. 3. Visca P, Seifert H, Towner KJ (2011). Acinetobacter infection an emerging threat to human health. IUBMB Life, 63(12):1048-54
4. 4. Silvia Munoz-Price L and Weinstein RA (2008). Acinetobacter Infection. N Engl J Med, 358:1271-81.
5. 5. Kempf M, Rolain JM (2012). Emergence of resistance to carbapenems in Acinetobacter baumannii in Europe: clinical impact and therapeutic options. Int J Antimicrob Agents, 39(2):105-14.
6. 6. T.R. Ministry of Health, General Directorate of Health Service (2012). Department of Health Service Standards National Nosocomial Infections Surveillance. Network (UHESA) Report, Summary Data 20.
7. 7. Corbella X, Montero A, Pujol M, Domínguez M.A, Ayats J, Argerich MJ et al (2000). Emergence and rapid spread of carbapenem resistance during a large and sustained hospital outbreak of multiresistant Acinetobacter baumannii. J Clin Microbiol, 38(11): 4086-95.
8. 8. Imperi F, Antunes LC, Blom J, Villa L, Iacono M, Visca P and Carattoli A. (2011). Thegenomics of Acinetobacter baumannii: insights into genome plasticity, antimicrobialresistance and pathogenicity. IUBMB Life, 63(12):1068-74.

9. 9. Playford EG, Craig JC and Iredell JR. (2007). Resistant Acinetobacter baumannii in intensive care unit patients: risk factors for acquisition, infection and their consequences. J Hosp Infect, 65(3):204-11.
10. 10. Aygun G, Demirkiran O, Utku T et al. (2002). Environmental contamination during a carbapenem-resistant Acinetobacter baumannii outbreak in an intensive care unit. J Hosp Infect, 52(4):259-62.
11. 11. Tatman-Otkun M, Gürcan S, Oze B et al (2004). Annual trends in antibiotic resistance of nosocomial Acinetobacter baumannii strains and the effect of synergistic antibiotic combinations. New Microbiol, 27: 21-8.
12. 12. Jellison TK, Mckinnon PS, Rybak MJ (2001). Epidemiology, resistance, and outcomes of Acinetobacter baumannii bacteremia treated with imipenem-cilastatin or ampicillin-sulbactam. Pharmacotherapy, 21: 142-8.
13. 13. Fishbain J & Peleg AY. (2010). Treatment of Acinetobacter Infections. Clinical Infectious Diseases, 51: 79-84.
14. 14. Batirel A, Balkan II, Karabay O, Agalar C, Akalin S, Alici O, et al. (2014). Comparison of colistincarbapenem, colistin-sulbactam, and colistin plus other antibacterial agents for the treatment of extremely drug-resistant Acinetobacter baumannii bloodstream infections. Eur J Clin Microbiol Infect Dis, 33(8):1311-22.
15. 15. World Health Organization. (2018). Global priority list of antibiotic-resistant bacteria to guide research, discovery, and development of new antibiotics. WHO. Health.
16. 16. Eze EC, Chenia HY, Zowalaty ME. (2018). Acinetobacter baumannii biofilms: effects of physicochemical factors, virulence, antibiotic resistance determinants, gene regulation, and future antimicrobial treatments. Infect Drug Resist, 11: 2277-99.
17. 17. Yolbaş İ, Tekin R, Güneş A, Kelekçi S, Şen V, Tan İ, Uluca Ü. (2013). Antibiotic susceptibilities of Acinetobacter baumannii strains in a university hospital. Journal of Clinical and Experimental Investigations, 4: 318-321.
18. 18. Kurtoğlu MG, Opus A, Kaya M, Keşli R, Güzelant A, Yüksekkaya Ş. (2011). Antibacterial resistance in Acinetobacter baumannii strains isolated from clinical specimens in a training and research hospital. (2008-2010). ANKEM Journal, 25:35-41.
19. 19. Cesur S, Irmak H, Yalçın AN, Berktaş M, Baysan BÖ, Kınıklı S, Demiröz AP. (2017). Antibiotic susceptibility of Acinetobacter baumannii strains isolated from various culture samples of patients hospitalized in the intensive care unit. Middle East Medical Journal, 9(2): 51-5.
20. 20. Kalem F, Ertuğrul Ö, Dağı HT. (2017). Çeşitli klinik örneklerden izole edilen Acinetobacter baumannii suşlarında antibiyotik direnci. Abant Med J, 6(1):20-25.
21. 21. Motbainor H, Bereded F, Mulu W. (2020). Multi-drug resistance of blood stream, urinary tract and surgical site nosocomial infections of Acinetobacter baumannii and Pseudomonas aeruginosa among patients hospitalized at Felegehiwot referral hospital, Northwest Ethiopia: a cross-sectional study. BMC Infect Dis, 20(1):92.
22. 22. Laudisio A, Marinosci F, Gemma A, Bartoli IR, Montenegro N, Incalzi RA. The Burden of Comorbidity Is Associated with Antibiotic Resistance Among Institutionalized Elderly with Urinary Infection: A Retrospective Cohort Study in a Single Italian Nursing Home Between 2009 and 2014. Microb Drug Resist. 2017 Jun;23(4):500-506. doi: 10.1089/mdr.2016.0016.
23. 23. Fournier PE, Vallenet D, Barbe V, Audic S, Ogata H, Poirel L, et al (2006). Comparative genomics of multidrug resistance in Acinetobacter baumannii. PLoS Genet,. 2:e7.